Albion® Copper Bisglycinate: Research on Copper Status & Antioxidant Function

Key Takeaways

• Copper is essential for several enzymes involved in antioxidant defense, energy production, connective tissue formation, and iron metabolism.

• A randomized trial found that 2 mg of copper per day as copper glycinate increased erythrocyte superoxide dismutase 1 (SOD1) and plasma ceruloplasmin activity over eight weeks.

• The same trial did not find consistent improvements across the cardiovascular risk markers researchers measured.

• A separate trial in 16 healthy young women found that copper sulfate supplementation increased serum copper and erythrocyte superoxide dismutase activity at 3 mg per day, but increasing the dose to 6 mg did not produce further significant increases in these markers.

• These studies provide evidence that copper supplementation can affect selected biomarkers. They do not establish that higher copper intake improves long-term health outcomes.

• The published copper glycinate trial should not be interpreted as definitive clinical proof of Albion® Copper Bisglycinate's superiority because it did not establish a direct comparison with other copper forms.

• Human evidence comparing the bioavailability of different supplemental copper forms remains limited.
  
  

Copper is an essential trace mineral involved in antioxidant defense, energy production, connective tissue formation, and iron metabolism. Research on copper supplementation has investigated its effects on copper status and copper-dependent enzymes, including superoxide dismutase 1 (SOD1) and ceruloplasmin.

This article reviews published human research on Albion® Copper Bisglycinate Chelate and copper supplementation, focusing on copper status, antioxidant enzyme activity, and zinc-copper balance. It examines findings from clinical studies involving copper glycinate and copper sulfate, highlighting the limitations of current evidence and what research establishes about copper bisglycinate, comparative bioavailability, and copper-related biomarkers.

What Does the Research Show About Copper Bisglycinate?

Research on copper supplementation provides evidence that copper intake can influence certain biological markers, particularly enzymes involved in copper metabolism and antioxidant defense. However, the evidence needs to be interpreted carefully when evaluating a specific branded ingredient such as Albion® Copper Bisglycinate Chelate.

Copper is required for enzymes including copper-zinc superoxide dismutase (Cu/Zn SOD) and ceruloplasmin. These proteins have important physiological functions, making their activity useful to researchers studying copper status.

But changes in enzyme activity do not automatically translate into measurable improvements in cardiovascular health, energy, or other clinical outcomes.

The distinction is particularly important because research on copper supplementation is not necessarily research on Albion® Copper Bisglycinate specifically. Studies using copper sulfate, for example, provide information about copper supplementation but cannot establish the comparative performance of a copper bisglycinate ingredient

For more background, explore our guide to Albion® mineral technology and chelation.

Three questions therefore matter when assessing the evidence:

• Does supplementation change copper-related biomarkers?

• Do those changes improve meaningful health outcomes?

• Is there direct evidence that Albion® Copper Bisglycinate performs better than other copper forms?
  
  

Current human research offers some answers to the first question. The second remains less certain, and the third is not established by the studies discussed below.

The 2012 Randomized Trial: Copper Enzymes and Cardiovascular Markers

One relevant human study examined whether copper supplementation affected blood copper enzymes and cardiovascular health-related markers in healthy middle-aged adults with moderately high cholesterol.

DiSilvestro and colleagues published the randomized trial in Metabolism in 2012.

Study design

Participants received either a placebo or 2 mg of copper per day as copper glycinate for eight weeks. Researchers measured copper-related enzyme activities and several cardiovascular health markers before and after supplementation.

The study examined:

• Erythrocyte superoxide dismutase 1 (SOD1) activity

• Plasma ceruloplasmin activity

• C-reactive protein (CRP)

• Homocysteine

• Total cholesterol

• LDL cholesterol

• HDL cholesterol

• Oxidized LDL

What did the researchers find?

Copper supplementation increased the activity of two copper-dependent enzymes:

The findings suggest that additional copper can influence the activity of enzymes involved in antioxidant defense and copper metabolism.

However, the cardiovascular findings were more limited. The researchers did not observe consistent improvements across the cardiovascular markers measured.

2012 Trial at a Glance

What does this mean?

The trial supports a specific conclusion: copper supplementation can increase the activity of certain copper-dependent enzymes in the studied population.

It does not establish that copper supplementation prevents cardiovascular disease, improves overall cardiovascular health, or provides a general antioxidant benefit that can be measured as a clinical outcome.

There is also an important ingredient-specific limitation. Although Balchem cites this study in connection with its copper bisglycinate ingredient, the published intervention is described as copper glycinate. The study should not be presented as definitive proof that the branded Albion® ingredient is superior to other copper forms.

Reference: DiSilvestro RA, Joseph EL, Zhang W, Raimo AE, Kim YM. “A randomized trial of copper supplementation effects on blood copper enzyme activities and parameters related to cardiovascular health.” Metabolism. 2012;61(9):1242-1246.

What Did the 2005 Study Find About Copper Status?

A second relevant human study, published by Bügel and colleagues in the British Journal of Nutrition in 2005, examined copper supplementation in healthy young women.

Study design

The study included 16 women with a mean age of approximately 24 years. Researchers used a randomized crossover design in which participants completed three four-week intervention periods, separated by three-week washouts.

During the intervention periods, participants received:

• No supplemental copper

• 3 mg of elemental copper per day as copper sulfate

• 6 mg of elemental copper per day as copper sulfate
  
  

Researchers assessed copper-status markers and several cardiovascular risk-related measures.

What were the results?

The researchers found that the 3 mg daily dose significantly increased serum copper concentration and erythrocyte superoxide dismutase activity compared with the control period.

Increasing the dose to 6 mg per day did not produce a further significant increase in either of these markers.

The 6 mg dose was associated with an approximately 30% reduction in plasminogen activator inhibitor type 1 (PAI-1), a factor involved in regulating blood clot breakdown. However, the researchers found no significant effects on the other cardiovascular risk markers they assessed.

How should these results be interpreted?

This study provides additional evidence that copper intake can influence selected biomarkers in humans. It also illustrates why the dose and the particular outcome being measured matter.

The lack of further increases in serum copper and superoxide dismutase activity at the higher dose suggests that more supplemental copper does not necessarily produce a larger response in every biological marker.

The PAI-1 finding is noteworthy, but a change in one laboratory measure is not sufficient to establish a reduction in cardiovascular events or disease risk.

Most importantly for this article, the study used copper sulfate, not copper bisglycinate. It provides context about copper supplementation and copper status, but it cannot determine whether Albion® Copper Bisglycinate has better absorption or produces different clinical outcomes.

Reference: Bügel S, Harper A, Rock E, O’Connor JM, Bonham MP, Strain JJ. “Effect of copper supplementation on indices of copper status and certain CVD risk markers in young healthy women.” British Journal of Nutrition. 2005;94(2):231-236.

Does Copper Supplementation Improve Antioxidant Function?

Copper is part of Cu/Zn SOD, an enzyme that helps convert superoxide radicals into less reactive molecules. This makes copper availability relevant to the body's antioxidant defense systems.

The two human studies discussed above found increases in superoxide dismutase activity following copper supplementation. The 2012 copper glycinate trial also reported increased ceruloplasmin activity.

These findings are biologically meaningful because they demonstrate changes in the activity of copper-dependent enzymes. However, an increase in antioxidant enzyme activity is not the same as proof of reduced oxidative damage or improved long-term health.

Several distinctions are important:

• Enzyme activity: Measures how active a particular enzyme is under the conditions of the test.

• Oxidative stress markers: Assess selected processes associated with oxidative damage or antioxidant status.

• Clinical outcomes: Measure effects that matter directly to health, such as disease incidence, symptoms, or functional outcomes.
  
  

These categories are related, but they are not interchangeable.

In the 2012 trial, copper supplementation increased SOD1 and ceruloplasmin activity, yet the cardiovascular markers did not show consistent improvement. This is a useful example of why biomarker findings should not be overstated.

The available studies support a role for copper in normal enzyme function. They do not establish that taking extra copper beyond nutritional needs provides additional antioxidant protection for people who already have adequate copper status.

What Does the Evidence Say About Copper Absorption?

Absorption is an important consideration when comparing mineral supplements, but the evidence for copper differs from the evidence available for some other minerals.

Copper supplements are available in several forms, including copper sulfate, copper gluconate, copper oxide, and amino acid chelates such as copper bisglycinate.

These forms have different chemical structures. Nevertheless, the National Institutes of Health Office of Dietary Supplements states that human studies have not compared the bioavailability of copper across these supplemental forms.

That limitation matters when interpreting research on Albion® Copper Bisglycinate Chelate.

A study showing that copper glycinate changes enzyme activity demonstrates that the supplemental copper was biologically available in the study context. It does not, by itself, prove that copper bisglycinate is absorbed more efficiently than copper sulfate or other forms.

Similarly, the fact that an ingredient uses a defined chelated structure does not establish clinical superiority without direct comparative evidence.

The most defensible conclusion is that copper bisglycinate provides a specific amino acid chelated form of copper, while universal superiority in human absorption has not been established.

Learn more about Albion® Copper Bisglycinate chelation technology in our ingredient guide.

Can High Zinc Intake Affect Copper Status?

Yes. High zinc intake can interfere with copper absorption, and excessive use of zinc supplements over time can contribute to copper deficiency.

The NIH Office of Dietary Supplements notes that reductions in erythrocyte Cu/Zn SOD, a marker related to copper status, have been reported with zinc intakes of approximately 60 mg per day for up to ten weeks.

This is above the adult tolerable upper intake level for zinc of 40 mg per day, which includes intake from food, beverages, supplements, and medications.

The interaction is relevant because copper deficiency can affect several physiological systems, including normal blood cell formation, connective tissue function, and nervous system health.

However, this does not mean everyone taking zinc needs a copper supplement. The appropriate response depends on the person's total intake, duration of use, health circumstances, and whether a deficiency is present.

When copper deficiency is suspected, clinical assessment is more appropriate than automatically adding copper or assuming that a particular chelated form will correct the problem.

What Can and Cannot Be Concluded About Albion® Copper Bisglycinate?

The available research supports copper's essential biological role and shows that copper supplementation can change selected enzyme activities and other laboratory markers.

It is less conclusive about broader health benefits, and it does not establish that Albion® Copper Bisglycinate is clinically superior to other copper forms.

The distinction between ingredient identity and clinical evidence is central to interpreting these findings. Albion® Copper Bisglycinate Chelate has a defined amino acid chelated structure and is associated with the TRAACS® system, but those manufacturing characteristics do not independently demonstrate better clinical outcomes.

For consumers and supplement formulators, the evidence supports looking at the ingredient's form, elemental copper content, quality standards, and the research available for the specific outcome of interest.

Frequently Asked Questions

Is Albion® Copper Bisglycinate clinically proven to be better than other copper forms?

Current human evidence does not establish that Albion® Copper Bisglycinate is clinically superior to other copper forms. The available studies provide information about copper supplementation and selected biomarkers, but they do not establish universal superiority in absorption or health outcomes.

What did the 2012 copper glycinate study find?

The randomized eight-week study found that 2 mg of copper per day as copper glycinate increased erythrocyte SOD1 and plasma ceruloplasmin activity. It did not consistently improve the cardiovascular markers measured.

Does copper supplementation improve antioxidant function?

Human studies have found increases in the activity of certain copper-dependent enzymes after supplementation. These findings support copper's role in normal antioxidant enzyme function, but they do not prove that additional copper improves long-term health or provides extra protection in people with adequate copper status.

Is copper bisglycinate better absorbed than copper sulfate?

This has not been established by comparative human evidence. Studies using copper sulfate or copper glycinate cannot independently demonstrate that copper bisglycinate has superior bioavailability.

Can too much zinc cause copper deficiency?

Yes. Excessive zinc intake can interfere with copper absorption and contribute to copper deficiency over time. Long-term high-dose zinc use should be considered in the context of total intake and individual needs.

Should everyone take a copper supplement with zinc?

No. Copper supplementation is not automatically necessary for everyone who takes zinc. Decisions should account for total intake, duration of supplementation, individual circumstances, and clinical evidence of deficiency where relevant.

Final Thoughts

Human research shows that copper supplementation can affect selected copper-dependent enzyme activities, including SOD1 and ceruloplasmin. However, these biomarker changes have not consistently translated into improvements in the cardiovascular outcomes measured in the available trials.

For Albion® Copper Bisglycinate, the distinction between a defined chelated ingredient and proven clinical superiority remains important. The current evidence supports copper's essential biological role, but it does not establish that this form is universally better absorbed or produces superior health outcomes compared with other supplemental copper forms.

At Just Glow, we believe science-backed ingredients and evidence-based nutrition are the foundation of long-term wellness.

Explore our Albion® Copper Bisglycinate supplement today.